CLC bio Delivers Specialized Immunoinformatics Solution to Symphogen
News Aug 21, 2009
CLC bio has just completed a specialized immunoinformatics solution that is fully customized to fit into Symphogen’s proprietary Symplex™ technology for high throughput identification of antibodies with diversity and specificity customized to a particular therapeutic application.
CLC bio has developed a CLC Main Workbench plug-in, which is designed to optimize the end-to-end workflow and analysis pipeline when working with the large number of antibodies retrieved during the Symplex™ process.
“When investigating the diversity and complexity of disease-relevant antibody repertories from human donors, speed and quality are essential. Thus, the faster we can go through our initial bioinformatics workflow and identify a diverse panel of complementary antibodies of interest, the earlier we can compose the optimal recombinant polyclonal antibody (rpAb) drug lead candidate to advance into development - this is of course of the utmost importance to us” says Director of Antibody Discovery at Symphogen, Dr. Allan Jensen, PhD.
He continues, “CLC bio has fully integrated the workflow by automating all the steps in the downstream bioinformatics analysis process. Not only has this accelerated the research process tremendously by eliminating tedious and complicated manual procedures but it also removes the overhead of keeping third party software running and updated - and in turn it provides a high quality and robust workflow.”
Director of Consulting Services at CLC bio, Dr. Jannick D. Bendtsen, continues, “Where Symplex™ is a cutting-edge concept for testing on humans and in the lab, Symphogen’s new special plug-in is designed to analyze the sequencing data coming from all these research projects, and integrate them nicely into an end-to-end workflow. We are proud to deliver this intricate solution to Symphogen, which stresses the flexibility and stability that our overall bioinformatics platform provides, and we look forward to seeing Symphogen’s projects coming faster through their development phases.”
Algorithm Predicts Life Expectancy After Heart AttackNews
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more personalized assessments of people who are awaiting heart transplants, which in turn could enable health care providers to make better use of limited life-saving resources and potentially reduce health care costs.
Computation and Chemistry Combine to Create World-First Auxetic ProteinNews
A team of chemists at the University of California, San Diego (UCSD) has now designed a two-dimensional protein crystal that toggles between states of varying porosity and density. This is a first in biomolecular design that combined experimental studies with computation done on supercomputers. The research, published in April 2018 in Nature Chemistry, could help create new materials for renewable energy, medicine, water purification, and more.
Fructose Formula Poses Risk to Babies With Metabolic DisorderNews
Babies with inherited intolerance of fructose face a risk of acute liver failure if they are fed certain widely available formulas containing fructose, pediatricians and geneticists are warning. Baby formula manufacturers should remove fructose or sucrose, or explicitly label their products to allow parents to avoid those sweeteners if necessary, the doctors say.